© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
AAN
Peter Nakaji, MD: The State of Science for Epilepsy Surgery
May 29, 2020
The chair of the Department of Neurosurgery at Banner-University Medical Center discusses the current state of the science being done in the realm of epilepsy surgery.
Second Dose of Ubrogepant Is Safe and Effective in Acute Migraine
May 22, 2020
The study author, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of a pooled analysis of the ACHIEVE I and II studies of ubrogepant.
Andrew Blumenfeld, MD: Long-Term OnabotulimuntoxinA Use in the COMPEL Study
May 20, 2020
The director of the Headache Center of Southern California discussed the findings of the study, as well as what these data might suggest about how onabotulinumtoxinA fits into the shifting landscape of chronic migraine care.
Ofatumumab Shines in Pooled Comparative Analysis in Relapsing Multiple Sclerosis
May 20, 2020
The neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed how the agent might fit into the treatment landscape if its sBLA is approved by the FDA later this year.
Nusinersen Shows Efficacy in Infantile- and Late-Onset Spinal Muscular Atrophy
May 19, 2020
The new data further cemented the therapy’s consistent safety profile from previous studies as well as demonstrated a newfound durability in patients with later-onset spinal muscular atrophy.
Steve Chung, MD: Cannabidiol in Tuberous Sclerosis Complex
May 13, 2020
The neurologist at Banner-University Medicine Neuroscience Institute offered his perspective on data from an open-label safety assessment of cannabidiol (Epidiolex) in the treatment of tuberous sclerosis complex.
Jessica Ailani, MD: Optional Second Dose of Ubrogepant in Acute Migraine
May 12, 2020
The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of an analysis from the ACHIEVE studies of ubrogepant.
BAN2401 Linked to Persistent Negative Amyloid PET in Alzheimer Disease
May 12, 2020
Despite patients being off treatment for an average of 23 months, patients treated with Eisai’s BAN2401 remained amyloid PET negative in an open-label extension preliminary analysis.
Eteplirsen Slows Pulmonary Decline in Duchenne Muscular Dystrophy
May 11, 2020
The FDA-approved treatment was associated with a clinically meaningful delay in needing continuous ventilation among patients with Duchenne muscular dystrophy.
Nina Riggins, MD, PhD: The Effect of Dihydroergotamine Infusion Rates
May 08, 2020
The headache specialist at UCSF discussed the findings of a retrospective assessment of the impact of the infusion rate of dihydroergotamine (DHE) on inpatient treatment outcomes.